Cytokinetics Shares Slide as Novartis Reportedly Shies Away From Deal
By Colin Kellaher
Cytokinetics shares tumbled more than 20% on Thursday amid waning expectations that Swiss drugmaker Novartis would strike a deal to buy the heart-drug developer.
The Wall Street Journal on Monday had reported that Novartis was near a deal to buy Cytokinetics, sending shares of the South San Francisco, Calif., company soaring.
However, no deal emerged over the past couple of days, and The Journal on Thursday reported that Novartis had backed away from its pursuit of Cytokinetics, which has been running a sale process.
Cytokinetics shares were recently changing hands at $78.08, down 23%, and well below the 52-week high of $110.25 they hit Monday after The Journal's initial report.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 11, 2024 12:47 ET (17:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks